
The evolution of poststroke recovery
UC expert featured in Medscape article
The University of Cincinnati's Joseph Broderick, MD, was featured in a Medscape article commenting on new treatments and advancements in the field of poststroke recovery research.
New research is challenging the idea that regaining limb mobility more than 6 months after a stroke was nearly impossible, including studies of noninvasive brain stimulation that pairs with physical rehabilitation to modulate disrupted neural networks.
Broderick noted determining the correct dose of stimulation will be key, as too much stimulation “can cause side effects that you don’t want.”
Other researchers are focused on using robotic therapy or interactive virtual reality (VR) gaming to help strengthen limbs and encourage patients to stick to their exercise regimen. Broderick noted that interventions like VR have a limitation of not being able to address language or vision deficits caused by stroke.
“There are limits to what we can recover from,” said Broderick, professor in UC’s Department of Neurology and Rehabilitation Medicine in the College of Medicine, director of the UC Gardner Neuroscience Institute and a UC Health physician.
Moving forward, Broderick said gene therapy could potentially help "spark motor recovery" in patients.
Featured photo at top of Dr. Broderick. Photo/Joseph Fuqua II/University of Cincinnati
Related Stories
UC marks 4 years saving lives with mobile stroke unit
August 15, 2024

The University of Cincinnati's Christopher Richards spoke with Local 12 about the four-year anniversary of the mobile stroke unit that can bring the emergency department directly to patients.
Trial finds new drug safe, effective to treat deadliest form of epilepsy
October 23, 2024

MSN highlighted research presented by the University of Cincinnati’s Brandon Foreman that found ganaxolone is a safe and effective treatment for refractory status epilepticus.
WLWT: UC hosts RESET epilepsy trial
May 3, 2023
WLWT spoke with the University of Cincinnati's Brandon Foreman about a clinical trial testing a new treatment for status epilepticus, the most severe and deadly form of epilepsy.